Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Descriptor ID |
D017326
|
MeSH Number(s) |
E05.318.760.250.500.220 N05.715.360.775.088.500.220 N06.850.520.450.250.250.220
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in this website by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 2 | 2 |
2009 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2011 | 0 | 2 | 2 |
2013 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 0 | 3 | 3 |
2018 | 0 | 2 | 2 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
-
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul; 25(7):e308-e317.
-
Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul; 25(7):e318-e330.
-
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis. Ann Pharmacother. 2022 05; 56(5):572-581.
-
Application of tumor treating fields for newly diagnosed glioblastoma: understanding of nationwide practice patterns. J Neurooncol. 2018 Oct; 140(1):155-158.
-
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Rheumatology (Oxford). 2018 01 01; 57(1):125-133.
-
Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 01; 118(2):162-170.
-
Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes. Am J Health Syst Pharm. 2017 Jul 15; 74(14):1045-1052.
-
Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Arthritis Rheumatol. 2017 04; 69(4):785-790.
-
OnabotulinumtoxinA for Treatment of Moderate to Severe Crow's Feet Lines: A Review. Aesthet Surg J. 2016 May; 36(5):591-7.